(CercleFinance.com) – The Theradiag share rose slightly by 0.7% on Monday on the Paris Stock Exchange, investors being reassured by the unsurprising activity figures published in the morning by the diagnostics specialist .
The group reported annual revenue of 12.2 million euros for the 2022 financial year, up 9.7%, in particular under the effect of solid export performance ( excluding the United States) materialized by an increase of +23.3%.
In ‘theranostics’ (combination of treatment and diagnosis that measures the effectiveness of biotherapies in the treatment of chronic diseases and allows their proper implementation), growth reached 10.1%
The historical in vitro diagnostics business posted sales up 9.2% to 5.8 million euros.
As of December 31, 2022, Theradiag’s cash amounted to 6.4 million euros compared to 7.1 million euros as of December 31, 2021, a level deemed ‘in line with the company’s operating plan’.
At the end of its public purchase offer (OPA), closed last week, Biosynex held more than 68.8% of the capital and at least 68.6% of the voting rights of Theradiag, which means that the condition minimum requirement the offer is met.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about THERADIAG in real time: